Published in J Immunol on May 01, 1991
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 2.91
Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med (1999) 1.82
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun (2009) 1.74
Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc Natl Acad Sci U S A (2011) 1.62
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol (2000) 1.47
Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol (2011) 1.46
The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J (2011) 1.19
Progress and controversies in developing cancer vaccines. J Transl Med (2005) 0.93
CD4 T-cell immunotherapy for chronic viral infections and cancer. Immunotherapy (2013) 0.85
The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens. Br J Cancer (1999) 0.83
Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. Prostate (2002) 0.79
Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PLoS One (2014) 0.79
CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination. PLoS One (2012) 0.78
The Transitional Endoplasmic Reticulum ATPase p97 Regulates the Alternative Nuclear Factor NF-κB Signaling via Partial Degradation of the NF-κB Subunit p100. J Biol Chem (2015) 0.78
Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma. Br J Cancer (2006) 0.75
DNA data bank of Japan (DDBJ) in collaboration with mass sequencing teams. Nucleic Acids Res (2000) 15.69
DDBJ in the stream of various biological data. Nucleic Acids Res (2004) 6.24
Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A (1971) 5.38
DNA Data Bank of Japan at work on genome sequence data. Nucleic Acids Res (1998) 4.43
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
DNA Data Bank of Japan (DDBJ) in XML. Nucleic Acids Res (2003) 3.87
Cellular immunity against tumor antigens. Adv Cancer Res (1969) 3.70
DNA Data Bank of Japan (DDBJ) for genome scale research in life science. Nucleic Acids Res (2002) 3.64
Abrogation of cellular immunity to antigenically foreign mouse embryonic cells by a serum factor. Nature (1969) 3.20
DDBJ in collaboration with mass-sequencing teams on annotation. Nucleic Acids Res (2005) 3.14
Immunological enhancement as studied by cell culture techniques. Annu Rev Microbiol (1970) 3.12
Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms. Int J Cancer (1971) 3.06
Genetic testing: a round table conversation. Part I. Intern Med J (2004) 2.96
Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int J Cancer (1971) 2.88
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A (1999) 2.87
Studies on cellular immunity and its serum mediated inhibition in Moloney-virus-induced mouse sarcomas. Int J Cancer (1969) 2.80
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol (1974) 2.68
Cellular and humoral immunity to different types of human neoplasms. Nature (1968) 2.40
Cell surface antigens of human melanoma identified by monoclonal antibody. Proc Natl Acad Sci U S A (1979) 2.40
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol (1997) 2.38
Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens. Proc Natl Acad Sci U S A (1969) 2.28
Phosphorylation of synthetic peptides by a tyrosine protein kinase from the particulate fraction of a lymphoma cell line. Proc Natl Acad Sci U S A (1982) 2.25
Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci U S A (1980) 2.14
Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci U S A (1968) 2.12
Phytochromes confer the photoperiodic control of flowering in rice (a short-day plant). Plant J (2000) 2.02
Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res (2000) 2.02
Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med (1994) 1.93
The x-ray structure of an anti-tumour antibody in complex with antigen. Nat Struct Biol (1995) 1.76
Elution of "blocking factors" from human tumors, capable of abrogating tumor-cell destruction by specifically immune lymphocytes. Int J Cancer (1972) 1.76
Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res (1986) 1.75
In vitro studies of immune reactions against autochthonous and syngeneic mouse tumors induced by methylcholanthrene and plastic discs. Int J Cancer (1968) 1.73
Genetic testing: a round table conversation. Part II. Intern Med J (2004) 1.71
Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci U S A (1981) 1.70
Immunological tolerance: "forbidden clones" allowed in tetraparental mice. Proc Natl Acad Sci U S A (1971) 1.67
Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A (1987) 1.61
Costimulation of T cells for tumor immunity. Immunol Today (1993) 1.57
Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res (1990) 1.57
Cellular immunity and its serum-mediated inhibition in Shope-virus-induced rabbit papillomas. Int J Cancer (1969) 1.56
Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol (2000) 1.53
Relationship between accreditation scores and the public disclosure of accreditation reports: a cross sectional study. Qual Saf Health Care (2005) 1.51
A comparative study of cephradine, amoxycillin and phenoxymethylpenicillin in the treatment of acute dentoalveolar infection. Br Dent J (1993) 1.50
The extent of lymph node dissection for colon carcinoma: the potential impact on laparoscopic surgery. Cancer (1997) 1.49
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (1993) 1.47
Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci U S A (1991) 1.47
Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. Proc Natl Acad Sci U S A (1986) 1.46
Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. J Exp Med (1978) 1.46
Human melanoma-associated antigen p97 is structurally and functionally related to transferrin. Nature (1982) 1.45
Neonatally induced allograft tolerance may be mediated by serum-borne factors. Nature (1971) 1.43
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A (1988) 1.41
Antibody response of mice to chemically induced tumors. Proc Natl Acad Sci U S A (1978) 1.41
Salinomycin, a new polyether antibiotic. J Antibiot (Tokyo) (1974) 1.40
Cell-mediated immunity against antigens common to human colonic carcinomas and fetal gut epithelium. Int J Cancer (1970) 1.40
Genome Information Broker for large and small genomes. Trends Genet (1997) 1.40
Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol (1994) 1.39
Protein antigens of normal and malignant human cells identified by immunoprecipitation with monoclonal antibodies. J Biol Chem (1980) 1.37
A microassay for antibody binding to tumor cell surface antigens using 125I-labelled protein a from Staphylococcus aureus. J Immunol Methods (1977) 1.36
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35
Myxofibrosarcoma with an infiltrative growth pattern: a case report. Jpn J Clin Oncol (2000) 1.33
Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines. Proc Natl Acad Sci U S A (1992) 1.32
Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma. Int J Cancer (1973) 1.30